GSK sells Ribena and Lucozade

<p>The brands have been bought by Suntory.</p>

Japanese beverages firm Suntory has confirmed the purchase of soft drinks brands Lucozade and Ribena from GlaxoSmithKline (GSK).

Suntory, which already owns beverage firm Orangina Schweppes, stated that the £1.35 billion deal will help it to expand into new markets.

David Redfern, GSK's chief strategy officer, described Ribena and Lucozade as being "iconic" brands, adding: "Now is the right time to sell them as we increase the focus of our consumer healthcare business."

He also noted the future of Lucozade and Ribena is in good hands as Suntory already has a strong reputation in the drinks business.

On the back of the sale of Ribena and Lucozade being announced, the share price of GSK was slightly down today (September 9th).

At 16:27 BST, its stocks were selling for 0.73 per cent lower than at the start of the session.

Find up to date information on the FTSE 100 and spread betting strategies at City Index

Build your confidence risk free
Join our live webinars for the latest analysis and trading ideas. Register now

StoneX Financial Ltd (trading as “City Index”) is an execution-only service provider. This material, whether or not it states any opinions, is for general information purposes only and it does not take into account your personal circumstances or objectives. This material has been prepared using the thoughts and opinions of the author and these may change. However, City Index does not plan to provide further updates to any material once published and it is not under any obligation to keep this material up to date. This material is short term in nature and may only relate to facts and circumstances existing at a specific time or day. Nothing in this material is (or should be considered to be) financial, investment, legal, tax or other advice and no reliance should be placed on it.

No opinion given in this material constitutes a recommendation by City Index or the author that any particular investment, security, transaction or investment strategy is suitable for any specific person. The material has not been prepared in accordance with legal requirements designed to promote the independence of investment research. Although City Index is not specifically prevented from dealing before providing this material, City Index does not seek to take advantage of the material prior to its dissemination. This material is not intended for distribution to, or use by, any person in any country or jurisdiction where such distribution or use would be contrary to local law or regulation.

For further details see our full non-independent research disclaimer and quarterly summary.